Techno Medica Co., Ltd.
Notice Regarding Differences Between Interim Earnings Guidance and Actual Results for the Fiscal Year Ending March 2027 Second Quarter (Interim)
Net sales exceeded guidance by 93 million yen versus the previous forecast, and operating income, ordinary income, and interim net income also exceeded guidance. There is no change to the full-year earnings guidance at this time. A portion of selling expenses was capitalized as fixed assets, contributing to expense reduction. Domestic sales are solid.
Key Figures
- Net sales: 4,453 million yen
- Operating income: 468 million yen
- Ordinary income: 485 million yen
- Interim net income: 321 million yen
- Interim net income per share: 48.94 yen
AI要約
Overview of Results
For the second quarter of the fiscal year ending March 2027, results were net sales of 4,453 million yen, operating income of 468 million yen, ordinary income of 485 million yen, and interim net income of 321 million yen, exceeding the previous guidance. Net sales exceeded guidance due to strong domestic sales of blood collection tube preparation equipment/systems and specimen testing devices, and on the expense side, selling, general and administrative expenses decreased due to capitalization of a portion of R&D expenses as fixed assets, causing profit metrics to surpass guidance. There is no revision to the full-year earnings guidance at this time.
Outlook and Factors
Although there is no change to the full-year guidance at present, the strong sales trend in the first half and the impact of expense treatment may continue to contribute positively to profits. The foreign exchange impact is unclear based only on the provided rate information, but strengthened domestic sales are expected to continue supporting performance.
Techno Medica Co., Ltd.
Company overview · Stock price · Financial data · All IR
